VolitionRx Limited (VNRX) 15 Aug 242024 Q2 Earnings call transcript

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the VolitionRx Limited Second Quarter 2024 Earnings Conference Call. [Operator Instructions] This conference is being recorded today, August 15, 2024.

I would now like to turn the conference call over to Louise Batchelor, Group Chief Marketing and Communications Officer. ahead. go Please

welcome, VolitionRx and today's conference earnings Thank everyone, for Limited. call you, to

begin, remind XXXX. will Before of like Litigation harbor I'd we to Private the discussed covered the Securities this provisions statements of the Act everyone on conference forward-looking call of include Reform under safe information some that

these these have information currently events, available These statements beliefs involve our concerning upon on statements our as well views us. and used Because statements uncertainties are based as reflect current assumptions assumptions. we risks, to future

Actual number results, future to cause results on expressed results may future vary by events or performance significantly the of based a implied be or from statements. or may factors different achievements materially that these actual

operations on and Exchange annual any in our of various made any identified Securities with not We've most call. undertake during Form the Form to XX-Q quarterly obligation our report reports other on filings We do and the update risk factors Commission. with this statements XX-K, recent forward-looking course associated

Reynolds, Executive Cameron will to Hughes, for Group Terig provide key before of a discussion Group program. results, ahead trials clinical Medical first Andrew will along open a Chief of quarter about back Volition's second commentary XXXX. will Chief Chief look indeed, half and Retter, Officer then upcoming Financial our and financial for Officer, cover with the operating providing Then activities highlights Officer, call, milestones. Dr. and the recent a passing to our Cameron President the finance

session. to conference open the then will question-and-answer call We a

the now Cameron. over hand I'll call to

the through XXXX for your Earnings and worldwide improve everyone, novel season. for you, appreciate Volition's platform. lives millions support people busy mission of the Call given our helping save your in to continued earnings of We today. you us advance call to and Quarter outcomes Second animals Thank time, and Lou, thank our epigenetics Thanks, joining

Vet did Nu.Q of to June XXXX, XX,XXX whole of I'm XXXX. that licensing versus we this our XXXX. the tests cancer than than cancer Through we and delighted tests in distribution of about more year we the have half launch year, veterinary of year we have successfully first full supported more Nu.Q sold test, XX,XXX This tests sold partners and the the for end in

a Antech as of U.S. Diagnostics, the and Mars announced as the team in-house countries list Nu.Q tests, the my Group, as The Singapore. as well launch not India Vet. also actively list far part price expanding. but of of to in country, $XX Petcare ever Australia, marketing afield test of very is Europe, home Vet at The only and been compelling very the Antech has the

at the are very cancer Fujifilm Vet After marketing are test $XX. Vet the now test the And initial good country-wide on announced Nu.Q to below X, also Japan. so July launch market watch. pricing to the of another from exciting in test feedback Systems bet they aggressively vets,

our pillars potential ensure significantly invested to robust scientific support clinical evidence we our to have and have years breakthrough and product out over We recent help to build the technologies.

in quarter significant second the for property readying make During we of intellectual licensing. and to continued our products including progress technologies, XXXX, our

patents patent of as pending granted XX with portfolio patent comprises further a families, XX XX patents Our June XXX worldwide.

acknowledge We notably scientific to the like source Property, of Jake this our Micallef, Mallalieu. Catherine the our Head team, work and rich take believe provide I'd all to Intellectual advantage, competitive Dr. of of a and hard to opportunity

adviser our to act include help as first will been the half of Volition Our our licensing space. recently PharmaVentures deal to has the second negotiating in to licensing to secure that focus human an And XXXX in end, deals. engaged

and strategic oncology advisory seek a international alliances. potentially as network extensive licensing, groundbreaking that and commercialize record means us Capture-PCR track to to ideally support in partnering we a dealmaking placed proven is in and is our portfolio. it experience with company respected PharmaVentures PharmaVentures specialist

now later Andy, for questions, the summary to industry for to to return will your of will Dr. also interest rooms, over in data oncology, I you. the already where received call data pass a only and we to of have discuss upcoming milestones Retter for from but over inclusion I for but sepsis, expressions future in key not answer players.

Thank everyone. you, morning, and good Cameron,

risk those our multiple organ to risk focus develop of treatment. is at progressing disease to in of Nu.Q progression low-cost the and failure addition NETs, particularly test a routine to monitoring response For the stratify to sepsis, to

made goals have second quarter. towards ambitious excellent achieving these the during We progress

with have We summer, the to studies after this anticipated October be confidential and XXXX. Conference is data publication sets expected data large for ESICM room a many number of the in extensive available

mortality, organ outcome In of line emergency all the correlating and with of with will stay these the in date, we summary, are in the to both of department, within and data covering ITU outcome severity, disease in across XX-day support, mortality, patients critical studies all critical measures care duration care measures for NETs have definition. Nu.Q length with hospital, key Sepsis-X

patients. first X,XXX have studies X Our over

with we We on The run an extremely admission of of and source the and believe by and insight this value of data, longitudinal length month and being is our goal both the resolution data stay. the These of end been enter cohorts are September. high the KOLs data processed. being to The well characterized, ready rich samples will finalized room HX.X. with shared data extremely the it have analysis throughout to the in into and all be completed have

Preliminary promising results consistent. cohorts and across are the

United the closed, including almost to from than last and study into study patients States data extended sicker patients, emergency for study the the for reported analysis to this be has complete. we department initiated Recruitment quarter, in ITU rather now include and the patients. is DXOCRO I As simply

member. consortium in nature, project This of leader, patients X,XXX Again, study. a approximately Djillali a Our an our with is is project which of with longitudinal scale, Professor study key France resolution progressing ongoing of it's in prospective the large opinion Volition is high in Annane well.

an have analysis data September. XXX added leader and key and performed upcoming with opinion in This team, workshop closely room confidential over his our be interim Working the Paris in shared will to at Professor we of Annane patients.

have good to the reported to management. the hope disordered Hemostasis. disease for providing publications, to during neutrophil therapeutic its findings further biology published at better and novel context and factors diseases. risk progress. strategies becomes in when physiology paper and targets, we We sepsis importance in and was of understand it regards again our second investigating and Thrombosis Zukas intervention and novel made quarter identify With The our detailed emphasized model, synthetic Journal of the

for The peer by paper positive Chromatin Human and second PMA-induced Neutrophils currently far, Primary Complex Dynamics Atteberry so feedback entitled and is received bioRxiv. available has NETosis review is to of on Understanding during review out

all of based our validity assay, paper. a not initial of have only great and the believe These underline now We to our the pipeline of also key excellence, Nu.Q opinion NETs leaders partners. licensing to partners or interest, off potential licensing centers papers Zukas have scientific and we we our but

role again event We soon. investigating Singer on a working perspective, from Professor with the to of sepsis. Professor following see on have NETs article, I Mervyn exploring been Finally, from and last the in on KOL year, bioRxiv hope review Annane a publication this

by Leader Again, workshop. September, Djillali second attended Key world it our chaired the Annane in Opinion of on by are we forward, Professor be leading sepsis. Looking will hosting experts and some

innovation from During sharing of our as well the our session, be extensive work some our will we recent significant findings America. from team key the studies as in

the I Group to XX management event, NETs KOL that from the potentially was year's impression breakthroughs that Nu.Q would represents of like biggest one in sense sepsis years. reiterate -- the the last last in whole

studies I intensive a will October, statement number reported bold due presented symposium to the conferences our and of to data We and the Care the support truly at in care evidence is view. largest satellite be Intensive the could of our by new excellence we earlier one anticipate European this be in hope correct, of the of Medicine, Volition provide the centers Society world. mentioned clinical In this

be half proud the for There'll first to Nu.Q many details it's sepsis. be very and NETs going satellite to be our are of We follow, a year but second busy sponsoring to symposium. more very

of for Nu.Q partners interest to build and help momentum to keen date, these negotiations activities continue and and to solidify all the with us discussions NETs. expect to further We our licensing

study and to Moving diagnosis look Oncology publication Lyon, Civils both just Hospices made solid out in also their and flag progress to in in review Lyon, Society earlier shortly de centers management PROLONG from submit clinical patients. Nu.Q peer data for of with hopefully utility be Medical cancer cancer. our of much team upon lung enticing The completed and We've for team present findings thereafter. the European will ONCO something and in This the at and want of excellence and the it Nu.Q September, has one you the at September. for work very demonstrating the will of to this, for We builds the Capture-PCR.

and, on the be next study manuscript published expected lung from is cancer, few National the University been recently with Taiwan again, Sticking has weeks. completed the bioRxiv to within

the a manuscript completed we in and finalized ovarian speak. study Our have cancer is Lyon colleagues being on also as

weeks. further the data next or to be studies data room and added will to it much across the confidential So the board, and compelling PharmaVentures expected few be of added with in

Cancer. case So much of very this Nu.Q space for a watch

DNA before, liquid reported biopsy simple DNA a of a removal blood. novel for first fragments cancer-derived physical detection extracted then These Capture-PCR, method, for all mentioned with background from tumor-derived of same the We've test. are DNA isolation class sequence a low-cost involving PCR of and the in fragments

identify detected at of Volition Dr. solid number X a cancers, disease or at ground especially order. Micallef cancers, conduct centers small of very excellence short including and opinion has and associated key and leader Jake have a and tested to liquid larger of PCR team presented this looking we'll cancer-specific other the solid experiment earlier cohorts biomarkers cancers team in initial potential detecting disease. network. at conferences, and all-important in the The Stage this developing tests, stages and patient data associated range clinical continued and method the gained and method potential the a in of and studies are

paper the potential to submit this breakthrough an soon. incredibly discussions commercial method publication close are add wide ongoing partners. plan data to with be completing of to the licensing room and will important this a peer to for and a that believe our We support range From manuscript we review perspective,

proven Thank you technologies. lots in companies for to to great have be Lots in papers interest of highlighting patented NETs, very to potential our and added by supporting promise and to licensing this scientific much have of come I Nu.Q the space. just clinical and our to year-to-date, saying our ] rooms for want Nu.Q and Capture-PCR continue data [ data we materials that These conclude Cancer. new listening.

With you, over that, I'd the you Terig to report. to for pass Terig? finance like And Thank everyone.

will for Good thank the joining of summary a morning, financial you ended quarter and everyone, the June today. for XX, now call I XXXX. key provide results the

announced Volition in the payments is number ensuring our with one As space human are agreements. this more for first and Nu.Q we achieve cash results, activities and NETs, XXXX. are flow in working or quarter Cancer Nu.Q licensing the Key those milestone receiving entering or of to threats on of goal in into under agreements a aim Capture-PCR, continually positive supply

increasing obtaining annualized milestone nondilutive on government payments expenditures from prior $X and Vet Nu.Q cutting an further reduce Heska for remaining costs the basis year, million funding. to feline, versus million $XX of meaningful for by Receiving revenues,

for I'm report half $XXX,XXX, second period we $XXX,XXX, than of these XX% revenue made quarter the And perspective, the half totaled first a same of up last on revenue XXXX, progress the revenue XX% recorded delighted the during From approximately XXXX, of of approximately XXXX. higher And threats. of each versus first year. to we

the seeing are test in-house accelerate, U.S. primarily cancer in platform of by the we driven growth Antech's and revenue Europe on So their to Vet launch April. starting in Nu.Q

and continue to of monetize expenditure an our activities help property. deliver from and perspective, exciting that all action projects focused streamlining intellectual technologies aim have we on and ensure the our undertake a of will to Secondly, plans we our with thorough review

range perspective, our aware, funding second of was of XXXX year. than XXXX XXth as in have than same funding quarter second June throughout last company's agencies, way a favorable targeted including of of we successful quarter end as lower lower quarter of of to the From been the the And XX% or you a headcount of we U.S. the XXXX. operating were the nondilutive And on for securing fund the example, By X% history, strategic expenses terms. probably projects. year-to-date, government are co-fund have of some in

As agencies. we million have support in European received from a Belgian reminder, nondilutive previously funding various over $XX and

coming provide in We this on the updates further months. will

Subsequent comprises cash direct We proceeds, $X ended and purchase up aggregate in to of end, warrants and stock million $X $XX.X equivalents the care-focused with of cash gross issued to a upfront million. of to stock of quarter to the exercise potential registered basis the milestone-linked of quarter $XX.X full warrants million up approximately an health of common at in million additional a cash This we with to deal a offering fund. investment completed the closing, upon transaction. on and investment common investor gross in proceeds single aggregate

in hope, And our achieved of similar of the highlighted, XXXX, first veterinary with half finally, will human following, as deal the the we already approach second as our licensing in the we has Cameron in negotiating include space. focus a support PharmaVentures, space,

your thanks, Terig, Andy, for reports. Thanks, comprehensive and

our itself either year funding to in the each product milestone as as continues other USD XX As well measures out-licensing previously on be support revenues, cost million. and/or mentioned, pillar reduction of the to on through payments, focus getting nondilutive coming company-wide

to We've half also strategy to the through cash made has team aim progress goal required the strong progress in first is in quarter. to XXXX. strong ensure The getting monetize this made Volition flow in through IP second data our our Our support positive towards licensing agreements. the of XXXX is

such are will to second be deals. of Our licensing to the secure half focus with and space, human negotiating in our PharmaVentures in first deal the help working XXXX include we delighted

we commercializing accumulated of lot We towards negotiations and our Nu.Q NETs, experience will Vet, from us and to, move but various limited Nu.Q such technologies, our which supply not for licensing Nu.Q of Cancer believe a help have some Capture-PCR. other as

these complex. our support and As discussed, have discussions Andy rooms licensing our is to active both parties. preparing agreements interested and of and/or ongoing The with we and supply potential been data busy negotiations supplementing nature broad

indication. of imagine, discussing regional, options versus are there clinical nonexclusive, clinical national range versus from a can indications you global As we versus all exclusive, specific are

of far of a had progress on We are fronts. an thus have interest incredible amount making number our in strong and technologies

we to IP revenues. curve in would milestone our maximize believe we for we XX It's us months. our order this the the technologies monetization an exciting time payments royalties and expect, as ongoing payments up If licensing in the strategy with exclusivity, provide value through payments as and push next meaningful milestone of successful, ongoing very

it, the And there you to so drawing our over in today. call earnings of We pillars. to close, digest a much is this I'd like thank how much all appreciate call to for very given all joining

now Operator? questions. take will We

Company. Our line The Instructions] come questions with first Bruce the of [Operator from Benchmark Jackson

and in on like test launched And Antech of with focus product. -- I'd but control working that quarter. because to the a the this you've uptick April. is vet Japan uptake you're distribution nice extent, got out the to for We know I launching this partners, some had revenue your in

sight, increases what the we to of curve uptake be we you've could see quarters, And in at? kind going for looking couple of just just got line we if sequential of are potentially -- next revenue? So could

Thanks, very you Bruce. it quarter. I'll this Yes, uptick to Terig. good over was pass a Terig?

difficult curve it's know a But very looks you're Yes, right, to we uptake. that good like. saw what

difficult QX, that like from to line of revenue the think on double sort a continues straight Vet know about it's up was of in but QX I whether that.

going both the or just we over last we it for quarter. look Antech have because we've next of next Fuji and having line the to into you certainly like expect increase don't what the X launched couple got in but As of quarter said, quarters, sight direct that's to

But us So over looking increase seeing to is difficult of the point. some next this give there quarters. couple forward it at we're for to guidance

point the extremely of Antech, obviously, and that happy just And Yes. recently machine. the on launched we're care, with

cancer available game time think think hitting test running. is the can lab for has And it through a then a few history quite and first ground But little could first. care in I important, stock and I changer. they the can obviously be been living go really point aware a it's that I'm they But obviously, a that that because thing, very so lumpy in Fuji and reorder. months any of stock the also of for market it's any be the

really all extremely we're And But good it few have but the vets, happy. it's moment, it indications a very been at very the we a up, from an the we hopeful into to very kicks has of demand growing is over obviously good areas. could have quarters that we're little the sensitivity response specificity all XX% XX% be test. picking from But until bumpy -- next

then control see expenses, that And at being Terig. for statement more in do level expense that on to the one the we're running Great. Okay. operating The income going forward? for you quarter the be going

And each down now focusing peaked. have on previously, quarter. We're the coming I It's expenses commercialization. as mentioned

down the we'll So see coming continue those to costs are each coming down. And quarter. costs R&D

said, reduce We overall an And down. $XX those quarter, the started on bringing that annualized as I is the by least at really sort goal of million year-over-year basis. to expenses last

continuing the some actions of And end so of down over get the by the -- that those the continue to intent over you'll of balance of year. is see the the And year. will the impact

got we've million a in the overall year, expenses. next into Going $XX reduction

the important expensive. And now I emphasize. think, few climate to from Bruce, change money ago. raising We years is absolutely a it's understand probably Any

dollar we the accounts, going the else We've what we out. So spend. take just actually all spent we again, can are in days incredibly over careful every few last

very revenue a things had continue are which to those We've licensing room And sure we truly also are they're we but I close leading possibly everything cutting the technologies. fund. can, now is the ready. licensing making we the the to And deals, to being lot -- fantastic think I Because I and -- that think we're of interest. deals, we're getting breakthrough potentially think

You very from consistent promising. heard data Andy is and that the

And next well. so licensing the we're hopeful as get few very we quarters deal in a great can

So -- but it. we get absolutely

to we take can to everything reach doing out are we milestones. We these penny every we can sure make

And the months the milestones quarter. a few in big in there's few next quite

the extending them. So we're as possible much we make to get runway sure as

next questions zubkov Freedom [Operator with of ilya from Instructions] the Our line Broker. come

project funded and I valid the still have be wondering is funding. raised that each to is and last this it how question on if Earlier to a strategy? I aimed strategy week recently said was raised funding this was relates separately

absolutely are of we So self-funding. is key trying make the every one to sure areas

if absolutely So of looks the milestone lot are that going and the is, -- if it at fantastic you said, payments be moment, the as publishing we soon. data net a include we to

human we're my be can the I very and view, hopeful we've payments human that side think through well. that from years also point the the XX So we've around out in from deals, also very see wanted data coming everything you got Nu.Q on we it's It's in cancer cancer, solid -- start exciting of The now. also Nu.Q Capture-PCR, soon. been lung is which tumors, also cancer as will and and milestone in

-- So I that the the as well plausible as potentially as all grants governments. think self-funding and that, is well, it's very expecting from we're different

We a in. of large money have amount coming

We Europe again, and from different both government U.S. expect, agencies, in

as do the we data out, in moment, and it's get obviously, in milestones we wanted different the said next certain can a out, did get could to Andy of get the and fundraise, we areas but the make money expensive deal. licensing at everything So we couple to a all months these

same it's exactly strategy. I think So the

want Terig, to do you that? on speak

where bringing year. the positive costs of -- business, getting in think the you've year, focusing flow in licensing I That take us the Cameron, a Vet if getting done in. we'll funding successful, -- some next and to on then down the the and the covered of be that's to most getting think the it, should point space, we're revenue cash human government ramp Yes, I next

questions come Zacks the Small-Cap Ralston line with Our next Steven of from Research.

strength product -- was the lumpy. got You've to you breakdown here is there mentioned a your made we're to it way see different in Is distribution countries, release up where way through good to traction get where that -- But break a down ramping is? line. there the the channels, seeing -- some any up

is relatively seeing guidance yes. We're providing not the trends the on moment. moment, quarter-to-quarter it say, But yes, at we're to provide Cameron meaningful we've numbers moment still as of meaningful difficult is not sort mentioned. any at lumpy because still trends launch And at happening. that the the of And to any, got are from sort --

we'll put we something that's to be do a bit hoping traction. So when more

who and launches early -- ] But the range fair Mars. through. stocking it's bought obviously, is I think was with of which now this they've been had up, the working and Japan revenue other to IDEXX in say, We've [ a bump partners

picking So for -- progress preanalytics, up it very And the on the cat there and making making another launch product. the space, milestone Vet in much. cat payment of is also potentially we're we're also

for of different feedback the as ] can same work, tests as and plates they of can microtiter for all you workflow plates But into the XX [ plastic is also lot number tell trials But plates processes. well. a the when larger as ideal not you We've a not a get imagine, you samples, from in partners. The the from -- microtiter the work lab are machine. that

dogs. we've a do therefore, cats And have And So effort. to have cat we if of and the lot be working then able that now in automate spent time to a also we [ we the ] on product. expect test in

but slight, hopeful lot of some the can I work. doing get now that think point we're of we're pickup pickup. more from we Japan, is which And and So the care from too, a is

for really automate they're going is to into go. the I gear, kick to think labs the And high way to a

well. lot we've a background on that of doing as So work been

also perhaps monitoring new But enthusiasm our add with partners work, pick cats it's Fuji, in that course, X and we're Now And can very going and IDEXX. up. encouraged we into Antech to get obviously of hopefully we and traditionally year, to it by done the next next work of year.

but be strongly year. up of have So first I become But it's a it We've this of more upwards. once but done them the it their all will trend all think few than will quarters is launch all ordering half the obviously in there, last and more and in of much phases regularly. done down, year regular start

the XX% mean Concerning think made were progress sales where lagging R&D the like it sequentially. little program, was and and digit. the general between behind I tremendous in But XX% cost-cutting a I you reductions and marketing single and administrative expenses are that,

I to just like that? was significantly, clarify Do reduction Could expect like over R&D cost-cutting expect to months that implemented actually program a you where pick drop it sales up? marketing? you you expenses And ago. XX know -- and X-tier G&A cost and to whether some you

that think, coming happens that bit I up, R&D the are a so comes projects So natural sooner. finishing of some obviously, of in terms that -- is end to a just

rock can every look out. we little over the longer can find bit tackle. takes G&A turning we a are But to We cut what that under to obviously

down the naturally. projects quickly few roll perhaps as And just some the but will that months, so coming next of see those not we as R&D off as over

and of is, the we'll goal on to to to next over year. balance into the continue continue as But see said, year this we progress -- that

with A seem of about clarify be expect when milestone meet specific these funding recent warrants, nice B B you you Concerning warrants warrants? trigger The progress a quite the FDA milestones. approval. A -- have going which and to the to to you the what tail financing, Could please you these are give

Yes.

So the obviously, are commercially driven, you've warrants as said.

happy expressed are very -- are they So we've we actually.

the team and say partners. we data from [ the interest I'd ambulant are of a sepsis. think And that cancer have lot I ] scientific in about actually

X, we few So very or commercial means, do have doesn't expect them. the traction certainly -- deal next by mean, weeks a should few of we it but least strong take getting to a a at any be in I a in quarter

basically we some this realistic the in it's but a effort And a making that in spend in to an we to They and that, become on raise process Capture see data milestone, in the the it's so possibility. at guess, sure space. in I come human lot public, getting think sepsis, achievable of down was level. And Nu.Q, the a deal excellent having very lung, given I in value

that's in to the what milestones and doing to PharmaVentures sepsis. we're are tailored think have we and call And we right we warrants. we doing things those achieve, the So can

So that And the for quarters, quarters next away. away. a can that's that the in [ warrant But we we're warrant short kind meet ] A going X hopeful one then, that's that we in we're FDA, be call will the few said, that very years to when you and as of X is the longer but can hopeful term. obviously medium

million some reasonable completed in areas, thousand hundred extra as just of to dollars cash to a get -- cash financing? few in last get still interest they you bring the -- One question you some can management on the as financing. balances implementing well, sort $X program you off Are rates this

we spare interest-bearing have. where Yes, we do that any we have accounts put do some cash

managing are can. cash as as we the efficiently we yes, So

And to last going XXXX, present ESMO papers one right. there? in mid-September, what question. just All are Concerning how you many

Andy?

X paper There's present. being

predominantly So X results paper by -- it's being presented focusing cancer, lung well, very excited there, not there. focused we're and predominantly, the on

Intensive in that, to the with the early through Andy? which is European in go presentation And October. you want the October, Care, that, of and And do is Society one big that's

trials actually large symposium be clinical that our conducted far. -- got our from data sufficiently confident booked from we've in and that showing we've we're satellite a In where so data X we'll well, we've X upcoming trials scientific

work So there. lots lots and of

this to over to at time. no Cameron for closing questions remarks. further showing am hand I the back would like call Reynolds any I now

license milestones working thanks like are And on the reach you, front, the Volition. in very we of hard seeing. years, cost-cutting to human in we the on for we're everyone, we a human when with commercialization got space. the your started. XX Thank exactly range the can finally data happy PharmaVentures also but and with incredibly different assure wanted we what everyone, in we all We're interest it's front And I'd on to licensing where after of very, cancer products

as And sepsis we're happy data, well. extremely the as said, with Andy also,

So that's and all coming parties. number rooms publications, interested out frame in October a data in conferences the of September, in in large for time

be interesting an extremely of it the So end year. should

So for the earnings to forward November. next you time. call in I'm Thank looking your

you. teleconference. does your Thank We participation. conclude This today's appreciate

You lines of time. Enjoy disconnect may this day. your the rest at your